Because both of these publish complete pricing, you can do something this market rarely permits: measure exactly what dose-based pricing costs.
Precision Telemed charges $249.99 a month for compounded tirzepatide, flat from the 2 mg starter dose to the maximum clinical 15 mg, month-to-month with no subscription. It states plainly that most providers charge more as the dose increases and calls that a penalty for success.
Coby Health charges $239 at 2.5 mg, $299 at 5 mg, $329 at 7.5 mg, $379 at 10 mg and $439 at 12.5 mg and above — and publishes the titration schedule those doses follow, month by month.
The crossover happens immediately
Coby is cheaper for exactly one month. From month two at 5 mg it is $49 more expensive, then $79, then $129, then $189 a month at maintenance. Following Coby's own published schedule for a year — one month each at 2.5, 5, 7.5 and 10 mg then eight at 12.5 mg — costs $4,758 against Precision Telemed's $2,949 including its $199 first month.
Disclosure separates them further
Precision Telemed names Rush Pharmacy as its 503A compounder, states it never uses research-grade suppliers, and publishes eleven clinicians individually with training and NPI numbers verifiable in the national registry. Coby names no pharmacy and no clinicians.
Coby's site is also visibly unfinished: several FAQ answers on its compounded tirzepatide page remain unreplaced Lorem ipsum placeholder text, including the answers to whether a subscription is required and whether the medication is FDA-approved.
What Coby does better
It publishes the titration schedule with weeks attached, which is genuinely useful patient information, and it publishes a price at every dose rather than a single number. Its six-month same-dose bundles reach $179 a month at 2.5 mg — but those fix your dose as well as your price, which constrains your clinician.
Precision Telemed's own low-dose tier at $179.99 does the same thing more honestly, and is capped at 2 mg — below any dose studied for weight loss, as our microdosing guide explains.
Where a dose sits on the studied ladder
Move the slider to see whether a dose is one the weight-loss trials actually used. Doses below the studied range may still suit you — they simply have no trial result attached.
Standard titration step
Standard schedule: Weeks 1–4
The standard starting dose. Intended to build tolerance, not to produce weight loss.
In the trial programme behind Wegovy, adults reached a 2.4 mg weekly maintenance dose and lost an average of about 15% of body weight over 68 weeks.
Titration schedules are the standard ones for the approved products and are shown for orientation, not as a dosing instruction. Compounded products are not FDA-approved and your prescriber sets your schedule. Never change a dose on the basis of a web page.